Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Lysosomal Storage Diseases Therapeutics Market – Insights

Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders that result from defects in lysosomal function. The absence of lysosomal enzymes such as hydrolase responsible for breakdown of specific substrate, its activator or a transporter, result in accumulation of substrates, leading to LSDs.  Examples of LSDs include the mucopolysaccharidoses, mucolipidoses, oligosaccharidoses, Pompe disease, gaucher disease, Fabry disease, the Niemann-Pick disorders, and neuronal ceroid lipofuscinoses.

The global lysosomal storage diseases therapeutics market is estimated to account for US$ 7,217.9 Mn in terms of value in 2019 and is expected to reach US$ 15,734.5 Mn by the end of 2027.

Global Lysosomal Storage Diseases Therapeutics Market: Drivers

Significant prevalence of LSDs is expected to boost growth of the global lysosomal storage diseases therapeutics market over the forecast period. For instance, according to a report updated by National Center for Biotechnology Information, in January 2020, the prevalence of Fabry disease in white, male populations was 1:17,000 to 1:117,000. Moreover, classic Fabry disease mutations were evident in around 1:22,000 to 1:40,000 males and atypical presentations were associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females.

Moreover, increasing awareness regarding rare diseases is also expected to aid in growth of the market. For instance, the European Organization for Rare Diseases celebrates Rare Disease Day annually on the last day of the month of February.

North America region held dominant position in the global lysosomal storage diseases therapeutics market in 2018, accounting for 32.4% share in terms of value, followed by Europe.

Lysosomal Storage Diseases Therapeutics  | Coherent Market Insights

Global Lysosomal Storage Diseases Therapeutics Market: Restraints

Geographic dispersal of LSDs hampers efforts to understand the disease, given that certain rare diseases are even rarer in some regions. For instance, birth prevalence of LDSs differ considerably between various countries and population groups—Ashkenazi Jewish Ancestry have high prevalence of several genetic diseases, including some LSDs. Also, there is unusually high prevalence of Mucopolysaccharidosis (MPS) VI, GM1 gangliosidosis and fucosidosis in UAE, owing to ethnic isolation.

Moreover, high cost of enzyme replacement therapy for the treatment of LDSs is also expected to hamper growth of the market.

Global Lysosomal Storage Diseases Therapeutics Market: Opportunities 

R&D in LSDs is expected to offer lucrative growth opportunities for players in the global lysosomal storage diseases therapeutics market. For instance, in February 2020, researchers from BioStrategies LC, State University (U.S.), reported that biodistribution studies in LSD models provide evidence for the theory that the RTB-lectin transports corrective doses of enzymes across the blood–brain barrier for the treatment of central nervous system pathologies.

Moreover, use of advanced technologies in the treatment of LSDs is also expected to aid in growth of the market. For instance, in November 2019, researchers from Nacional Health Institute Doctor Ricardo Jorge, Portugal, reported that CRISPR-Cas9 has great potential for successful disease modelling of sphingolipidoses, an important group of rare diseases among LSDs.

Lysosomal Storage Diseases Therapeutics  | Coherent Market Insights

Enzyme replacement therapy segment in the global lysosomal storage diseases therapeutics market was valued at US$ 6,856.2 Mn in 2019 and is expected to reach US$ 14,938.7 Mn by 2027 at a CAGR of 10.0% during the forecast period.

Market Trends/Key Takeaways

The cost of therapies for the treatment of LSDs is high. For instance, Elaprase was regarded as one of the most expensive drugs by Forbes Index, which costs US$ 375,000 per year whereas Naglazyme costs US$ 365,000/patient/year.

In the U.S., Medicare and Medicaid programs provide good extent of reimbursement for LSDs. Around 84% of prescription drug plans covered under Medicare part D and part B provide reimbursement for orphan drugs for FDA approved indication. For instance, cost of Fabrazyme therapy reimbursed under Medicare part B is 80% of the allowable amount for Fabrazyme, for beneficiaries who administer Fabrazyme at a physician’s office or as hospital outpatient.

Regulations

North America

Lysosomal Storage Diseases Therapeutics  | Coherent Market Insights

Global Lysosomal Storage Diseases Therapeutics Market: Competitive Landscape

Major players operating in the global lysosomal storage diseases therapeutics market include, Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc.

Global Lysosomal Storage Diseases Therapeutics Market: Key Developments 

Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in January 2020, Quest Diagnostics acquired Blueprint Genetics to expand its product portfolio in genetic and rare diseases.

Major players in the market are also focused on adopting collaboration strategies to expand their portfolio. For instance, in 2019, Amicus Therapeutics, Inc. collaborated with the University of Pennsylvania, under which the company received disease-specific worldwide rights to the university’s Next Generation Gene Therapy Technologies from the Wilson Lab for LSDs and other twelve rare diseases.

The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes diseases such as Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes. Enzyme replacement is associated with fewer side effects than other treatment methods. Enzymes are obtained from sources such as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease.

Restraints of the Global Lysosomal Storage Diseases Therapeutics Market

Factors such as high cost associated with the enzyme replacement therapy and complex reimbursement scenario causing therapy to be excluded from coverage by insurers due to this being rare diseases, hamper growth of the market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global lysosomal storage diseases therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:
    • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • Substrate Reduction Therapy
      • Others
  • Global Lysosomal Storage Diseases Therapeutics Market, By Indication:
    • Gaucher's Disease
    • Fabry Disease
    • Pompe’s Syndrome
    • Mucopolysaccharidosis
    • Others
  • Global Lysosomal Storage Diseases Therapeutics Market, By End User:
    • Hospitals
    • Clinics
  • Global Lysosomal Storage Diseases Therapeutics Market, By Geography:
    • North America
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
        • Substrate Reduction Therapy
        • Others
      • By Indication
        • Gaucher's Diseases
        • Fabry Diseases
        • Pompe’s Syndrome
        • Mucopolysaccharidosis
        • Other
      • By End User
        • Hospitals
        • Clinics
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Shire plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Sanofi SA
    • BioMarin Pharmaceutical Inc
    • Actelion Ltd.
    • Raptor Pharmaceutical Corp.
    • Protalix Biotherapeutics Inc.
    • Amicus Therapeutics, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By Indication
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis
  4. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Enzyme Replacement Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Stem Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Substrate Reduction Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Gaucher's Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Fabry Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Pompe’s Syndrome
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Mucopolysaccharidosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Lysosomal Storage Diseases Therapeutics Market, By End User, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Lysosomal Storage Diseases Therapeutics Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Shire plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • BioMarin Pharmaceutical Inc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Actelion Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Raptor Pharmaceutical Corp.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Protalix Biotherapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amicus Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 24 figures on “Lysosomal Storage Diseases Therapeutics Market – Global forecast to 2027.

Frequently Asked Questions

The global lysosomal storage diseases therapeutics market is estimated to reach US$ 15,734.5 Mn by the end of 2027.
Major players operating in the global lysosomal storage diseases therapeutics market include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc.
High cost of enzyme replacement therapy for the treatment of LDSis one of the major factors that is expected to hamper growth of the market over the forecast period.
Significant prevalence of LSDs is one of the major factors that is expected to propel growth of the market over the forecast period.
The global lysosomal storage diseases therapeutics market is estimatedto account for US$ 7,217.9 Mn, in terms of value in 2019.
Among regions, North America held a dominant position in the global lysosomal storage diseases therapeutics market in 2018, accounting for 32.4% share in terms of value, followed by Europe.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner